新辅助化疗治疗123例乳腺癌的临床疗效分析

目的：探讨分析新辅助化疗治疗乳腺癌的临床疗效。方法：回顾性分析2009年1月-2014年1月来本院就诊的123例乳腺癌患者的临床资料，通过ER、PR、C-erbB2等免疫指标的检测和影像学分析，所有的患者均给予DTC化疗方案治疗3~4个疗程，观察患者治疗后的临床疗效。结果：123例乳腺癌患者经过规律的化学治疗后，其中完全缓解53例（43.09%）、部分缓解49例（39.84%）、疾病稳定18例（14.63%），疾病进展3例（2.44%），治疗有效率为97.56%；不良反应主要为胃肠反应、粒细胞减少、转氨酶升高等，经过对症治疗后症状好转。结论：新辅助化疗治疗乳腺癌能够明显改善患者的术后疗效，增加保乳手术的机会，值得临床推广。

Clinical Effect Analysis of Neoadjuvant Chemotherapy for the Treatment of 123 Cases of Mammary Cancer

Objective：To investigate and analyze the clinical curative effect of neoadjuvant chemotherapy for the treatment of mammary cancer.Method：The clinical data of 123 patients with mammary cancer in our hospital from January 2009 to January 2014 were analyzed retrospectively,all patients reviewed by detection of ER,PR, C-erbB2 and other immune parameters and imaging analysis.Patients received 3-4 courses of treatment by DTC chemotherapy,and the clinical curative effect after treatment was observed.Result：In 123 mammary cancer patients after chemotherapy,53 patients（43.09%）were completely relieved,49 cases reached partial remission（39.84%）,18 cases reached stable disease（14.63%）and 3 cases reached progression of disease（2.44%）.The adverse reactions were mainly gastrointestinal reaction,granulocytopenia and transaminase eleations,all the symptoms were improved after symptomatic treatment.Conclusion：Neoadjuvant chemotherapy for the treatment of mammary cancer can significantly improve the postoperative curative effect of patients and increases the chances of breast conserving surgery,is worthy of clinical promotion.